MBOT Stock Forecast: Microbot Medical, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Microbot Medical, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 15 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Microbot Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (43): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (8): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MBOT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MBOT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Nov 2026 | B. Riley Securities | Maintains | Buy | $4.00 → $3.00 |
| 17 Nov 2026 | Citizens | Maintains | Market Outperform | $2.50 → $2.00 |
| 23 Oct 2026 | Citizens | Initiates | Market Outperform | $2.50 |
| 21 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 14 Aug 2026 | B. Riley Securities | Reiterates | Buy | $5.00 → $4.00 |
| 3 June 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $4.00 |
| 14 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Feb 2026 | B. Riley Securities | Initiates | Buy | — |
| 3 Dec 2025 | Roth Capital | Initiates | Buy | — |
| 28 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Oct 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 May 2023 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MBOT.
This page is one stock. Monday covers all of them.
MBOT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MBOT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Microbot Medical, Inc. returned −60.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MBOT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 117.2×
- Price / book
- 0.8×
- EV / EBITDA
- —
Cheaper than 3% of US stocks
Cheaper than 78% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 1.9%
- Operating margin
- —
- Net margin
- —
Higher than 5% of US stocks
- Return on equity
- −26.3%
- Return on assets
- −17.6%
- Dividend yield
- —
Higher than 29% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Microbot Medical, Inc. has a market value of $49.7M.
Revenue in the twelve months to 31 Mar 2026: $105K.
Net income over the same four quarters: −$14.2M, a −13535.2% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$15.4M, after $155K of capital spending.
Microbot Medical, Inc. employs 43 people — $2K of revenue per employee.
Data provided by Twelve Data
MBOT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MBOT’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Microbot Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MBOT
What is the MBOT stock price forecast for 2026-2027?
The median 12-month analyst price target for Microbot Medical, Inc. is $3, with estimates ranging from $2 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MBOT stock a buy right now?
Of the 4 analysts covering Microbot Medical, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Microbot Medical, Inc. 15 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MBOT?
As at 21 Nov 2026, Microbot Medical, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (43 of 100).
Will MBOT stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $3, and Ticker Nerd's factor model ranks Microbot Medical, Inc. 15 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MBOT stock forecast for 2030?
No analyst covering Microbot Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBOT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $12 over the next 12 months.
How has MBOT stock performed over the past year?
Microbot Medical, Inc. returned -60.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Microbot Medical, Inc. do?
Microbot Medical Inc. is a medical device company focused on robotic technologies for minimally invasive procedures. Its current product portfolio centers on the LIBERTY Endovascular Robotic System, a disposable robotic platform designed to support catheter-based interventions in cardiovascular, peripheral, endovascular, and neurovascular care.
About Microbot Medical, Inc.
Microbot Medical Inc. is a medical device company focused on robotic technologies for minimally invasive procedures. Its current product portfolio centers on the LIBERTY Endovascular Robotic System, a disposable robotic platform designed to support catheter-based interventions in cardiovascular, peripheral, endovascular, and neurovascular care. The company also works on robotic endoluminal surgery devices aimed at improving precision and control in complex vascular pathways. Microbot Medical Inc. operates in the healthcare technology and medical devices market, where its systems are intended to help clinicians perform procedures with greater remote control and workflow efficiency. Headquartered in Hingham, Massachusetts, the company concentrates on developing specialized tools for interventional medicine and robotic-assisted procedure delivery.
CEO Mr. Harel Gadot · 43 employees · United States · https://microbotmedical.com